» Articles » PMID: 30499223

Predicting Risk of Pulmonary Infection in Patients with Primary Membranous Nephropathy on Immunosuppressive Therapy: The AIM-7C Score

Overview
Specialty Nephrology
Date 2018 Dec 1
PMID 30499223
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Pulmonary infection (PI) is the leading cause of death in patients with primary membranous nephropathy on immunosuppressive therapy. A rating score was thus developed to foresee the risk of PI in such patients.

Methods: We reviewed the charts of the pertinent patients treated during the past 3 years either with (n = 29) or without PI (n = 304). Clinical and laboratory data, the usage of cyclosporin A (CysA), and occurrence of PI were recorded. Cox regression analysis and receiver operating characteristic (ROC) curve were respectively used to identify the risk factors and assess their clinical relevance.

Results: The incidence of PI was 8.7% at 82.1 ± 20.9 days after the initiation of CysA regimen with a male predominance superimposed on smoking. Factors associated with PI were immunoglobulin G titer (hazard ratio = 4.56, 95% confidence interval = 2.31-8.95), plasma CysA concentration (3.71, 1.87-6.18), serum creatinine level (2.57, 1.31-5.82), CD4 /CD8 ratio (2.36, 1.26-6.06) and plasma albumin content (1.53, 1.05-3.25). These five factors, along with the male gender and smoking status, were granted different ratings after examined by the ROC curve and constituted the anticipating pulmonary infection in primary membranous nephropathy receiving CysA (AIM-7C) score. Accordingly, the respective percent composition of the infection and non-infection group was 0, 11.1%, 72.2%, 16.7% and 91.7%, 8.3%, 0, 0 in the order of low, moderate, high and utmost risk. Furthermore, eight new cases of PI were successfully predicted.

Conclusion: Our AIM-7C score may therefore help to predict the onset and facilitate the prevention of PI, a potentially life-threatening complication of the immunosuppressive therapy.

Citing Articles

Predicting susceptibility to COVID-19 infection in patients on maintenance hemodialysis by cross-coupling soluble ACE2 concentration with lymphocyte count: an algorithmic approach.

Yuan S, Meng F, Zhou S, Liu X, Liu X, Zhang L Front Med (Lausanne). 2024; 11:1444719.

PMID: 39540040 PMC: 11558530. DOI: 10.3389/fmed.2024.1444719.


Development and validation of a nomogram for predicting pulmonary infection in patients receiving immunosuppressive drugs.

Luo C, Zhang Y, Zhang J, Jin C, Ye X, Ren Y Front Pharmacol. 2024; 14:1255609.

PMID: 38293665 PMC: 10825965. DOI: 10.3389/fphar.2023.1255609.


Efficacy and safety of rituximab in elderly patients with membranous nephropathy.

Guo Y, Zhao H, Ren M, Wang Y, Wang L, Tang L Front Pharmacol. 2024; 14:1323334.

PMID: 38186651 PMC: 10771833. DOI: 10.3389/fphar.2023.1323334.


Pulmonary cryptococcosis closely mimicking lung cancer in a membranous nephropathy patient taking calcineurin inhibitor.

Zhao Z, Liu C, Yang J, Ren G, Zhang L, Wang T IDCases. 2023; 34:e01916.

PMID: 37867565 PMC: 10585382. DOI: 10.1016/j.idcr.2023.e01916.


Challenge of evolving infection in patients on hemodialysis: from the classic strain to the carbapenem-resistant hypervirulent one.

Zhou S, Ren G, Liu Y, Liu X, Zhang L, Xu S Int J Med Sci. 2022; 19(3):416-424.

PMID: 35370471 PMC: 8964319. DOI: 10.7150/ijms.69577.